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Abstract
Aim To assess the outcomes of sacral nerve stimulation
in adults with chronic constipation.
Method Standardised methods and reporting of bene-
fits and harms were used for all CapaCiTY reviews that
closely adhered to PRISMA 2016 guidance. Main con-
clusions were presented as summary evidence statements
with a summative Oxford Centre for Evidence-Based
Medicine (2009) level.
Results Seven articles were identified, providing data on
outcomes in 375 patients. Length of procedures and
length of stay was not reported. Data on harms were
inconsistently reported and heterogeneous, making esti-
mates of harm tentative and imprecise. Morbidity rates
ranged between 13 and 34%, with overall device
removal rate between 8 and 23%. Although inconsis-
tently reported, pooled treatment success was typically
57–87% for patients receiving permanent implants,
although there was significant variation between studies.
Patient selection was inconsistently documented. No
conclusions could be drawn regarding particular pheno-
types that responded favourably or unfavourably to
sacral nerve stimulation.
Conclusion Evidence supporting sacral nerve stimula-
tion is derived from poor quality studies. Three
methodologically robust trials are have reported since
this review and all have all urged greater caution.
Keywords Constipation, sacral nerve stimulation, neu-
romodulation, slow transit constipation
Introduction
Background and procedural variations
Sacral nerve stimulation (SNS) is well established for pelvic
urinary indications and for the treatment of faecal inconti-
nence when conservative measures have failed [1,2]. Its
role in the management of chronic constipation (CC) has
been studied since 2001 [3], based on a century of experi-
mental (multiple species: physiological and anatomical)
and clinical data that the sacral innervation has a prokinetic
effect on the rectum and colon via ascending colonic
nerves [4]. Brindley stimulation has exploited this effect in
small numbers of patients since the 1980s [5,6] andmech-
anistic studies from Adelaide of SNS effects on transit and
colonic contractile activity have confirmed potential to
increase anterograde contractile activity, reduce retro-
grade activity and speed transit [7]. SNS in its current
form uses chronic low amplitude stimulation of a chosen
sacral nerve root (usually S3) via a percutaneously placed
quadripolar electrode and implanted pulse generator.
There are procedural variations in terms of testing phase
(temporary wire ‘basic’ vs tined lead ‘advanced’ evalua-
tion) however the final assembly of components is uniform
reflecting a single current manufacturer (Medtronic Inc
Medtronic Limited, Watford, Herts, UK) for this clinical
indication.
Scope
The purpose of this study was to assess the efficacy and
harms of implanted SNS for adult patients whose main
presenting complaint is chronic constipation. Proce-
dures beyond the scope of this review include other
forms of neurostimulation (e.g. transcutaneous, vaginal,
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transanal, pudendal) and temporary SNS (i.e. where
data are only available during the testing phase).
Previous reviews
Two systematic Cochrane reviews have focused on
SNS for constipation, although faecal incontinence
was also included. The first (2007 [8]) concluded
that SNS can reduce symptoms in selected patients
with constipation, however this was based on a single
study which included two patients [9]. The second
included two RCTs and concluded that SNS did not
improve symptoms in patients with constipation,
although it recognised that the evidence was severely
limited [10].
Summary of search results and study quality
The search yielded a total of 20 citations for full text
review from a total of 121 abstracts found by initial
search criteria (Fig. 1: PRISMA diagram). From these,
only seven articles published between 2001 and 2015
contributed to the systematic review, providing data on
outcomes in a total of 375 patients (range 21–117
patients per study) (Table 1. Specific exclusions after
full-text review (and after exclusion of non-English lan-
guage publications: n = 1) [11] included nine studies
where the population sample was confirmed to be less
than 20 patients [3,12–19], one study [20] which was a
dual publication reporting a patient cohort that over-
lapped with another study [21] and one study where
results were combined for mixed indication s [22].
Study follow up ranged from 20 to 51 months.
The general quality of studies was poor due to inade-
quate description of methods. The seven included stud-
ies were all observational and all provided uncontrolled
LEVEL IV evidence, including one low quality prospec-
tive cohort study, two prospective and four retrospec-
tive case series. Mean patient follow up ranged from 20
to 51 months (median 27 months). All studies derived
from European centres, with three from UK and one
each from Spain, The Netherlands, Italy and Sweden.
Perioperative data
There were few data concerning standard perioperative
variables. All studies failed to include data on duration
of procedure, number of cases performed as day surgery
or duration of inpatient stay. A summary of periopera-
tive data is provided in Table 2. Peculiar to SNS, data
were reported on paradigm of test stimulation i.e. there
is more than one way to perform test stimulation. The
use of a previously described ‘standard procedure’ is sta-
ted in the methods section in only three studies [23–
25]. The duration of temporary SNS was reported as
2 weeks in two of the studies [25,26] and 3 weeks in
five of the studies [21,23,24,27,28]. The use of antibi-
otics during permanent SNS placement was reported by
one study only [23]. Type of anaesthesia for insertion
of temporary and permanent leads was reported in two
studies [20,27,28] and insertion of temporary wires in
the outpatient setting was described in one study [24].
Figure 1 PRISMA diagram of search results.
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Most studies used a tined quadripolar lead for perma-
nent stimulation. Five studies used a single lead
[21,23,24,28] whilst one study used bilateral stimula-
tion [27] and another used either single or bilateral
[25]. Some additional data pertaining to the cohort of
patients in the Govaert [21] study were reported in an
earlier study by Maeda et al. [20].
Summary evidence statements: perioperative data
1 Standard perioperative data (duration of procedure
and length of stay) were not reported by any study
(Level IV)
2 Where reported, general anaesthesia was used for
SNS procedures (Level IV)
3 The number of temporary unipolar SNS leads used
varied (1 or 2) between studies (Level IV)
4 Most studies used a single tined quadripolar lead for
permanent stimulation (Level IV)
Harms
Surgical morbidity, reported as overall procedural com-
plication rates, vary considerably with individual study
rates varying from zero to 39% [24] (Table 3). This
heterogeneity may have reflected (for example) differing
inclusion, procedural content, context of care, or
thresholds or conventions for recording complications.
Random effects meta-analysis found the overall compli-
cation rate to be 22.7% (95% CI: 12.9% to 34.1%),
I2 = 47% (Fig. 2). Device removal was similarly hetero-
geneous: the overall device removal rate was 14.4%
(95% CI: 7.8% to 22.5%), I2 = 47% (Fig. 3). There
were 51 re-operations: 30 for device removal although
five were replaced after resolution of pain or infection,
11 to move or replace the implant, 10 lead problems.
In addition six operations were carried out for treat-
ment of chronic constipation including three subtotal
colectomies [23,28], two stomas and one appendicos-
tomy [28]. Infection resulting in device removal was
reported in three patients. The commonest reason for
explantation was lack of effect and this was reported in
19 cases (Table 3). Two explantations were carried out
for pain associated with the implant and one for lead
migration. There appeared to be no relationship
between device explantation rate and length of follow
up (Table 1).
Patients with SNS for constipation had high levels of
reportable adverse events. Often this was resolved by
reprogramming but more than one-third required surgi-
cal intervention or discontinued therapy. Such data were
specifically reported in the sub-cohort of Govaert et al.
[21], reported separately by Maeda et al. [20] who car-
ried out a retrospective review of 38 patients who had
SNS for constipation and found that 22 patients (58%)
experienced at least one reportable event. The most
common event was lack or loss of efficacy. In 19 events
(33%), surgical intervention was required and the most
common intervention was electrode replacement (14
events). Three adverse events lead to discontinuation of
SNS. The remaining 35 patients were still using SNS
but with a variable degree of benefit.
Summary evidence statements: harms
1 Data on harms were inconsistently reported and
heterogeneous (Level IV).
2 The overall procedural complication rate resulting in
reoperation was typically 13–34% (Level IV).
3 Common complications resulting in reoperation
included lack of efficacy, infection, lead problems,
pain at site of implant, unwanted effects relating to
stimulation such as pain (Level IV).
4 Infection rates varied from 0 to 7% (Level IV).
5 Overall device removal rate was typically 8–23% at
mean follow up of 31 months (Level IV)
Table 1 All studies included in systematic review.
Author Year Centre Country
Total
N
Implanted
N FU*
Number at final
follow up N (%)‡ Design Level†
Kamm [23] 2010 St Marks UK 62 45 28 38 (61) PCH IV
Sharma [26] 2011 Hull UK 21 11 34 10 (48) RCS IV
Ortiz [24] 2012 Navarra Spain 48 23 26 14 (29) RCS IV
Govaert [21] 2012 Maastricht Netherlands 117 68 37 61 (52) RCS IV
Khan [27] 2014 Durham UK 22 12 20 12 (55) PCS IV
Ratto [25] 2014 Rome Italy 61 42 51 32 (76) RCS IV
Graf [28] 2015 Uppsala Sweden 44 15 24 11 (25) PCS IV
*Mean follow up in months.
†Oxford 2009 CEBM.
‡Based on intent to treat RCT, Randomised controlled trial; PCH, prospective cohort study; RCS, retrospective case series; PCS,
prospective case series; NR, Not recorded.
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Efficacy
Reported clinical outcomes varied in assessment tools
used across the seven studies (Table 4). Most com-
monly, these consisted of validated summative symptom
scores or questionnaires. These included the Cleveland
Clinic Constipation score [23,25], the SF-36 question-
naire [23,25], the Wexner Score [21,24], and PAC-
SYM and PAC-QOL questionnaire [27]. Additionally,
patient bowel diaries were used by several studies, either
as the principal outcome measure [26] or alongside
other measures [21,24,28]. The definition of treatment
success varied between studies. Of the two studies using
the Wexner score, one [24] defined success as a 30%
improvement in this score. The other [21] defined this
as a statistically significant reduction in score from base-
line. Kamm et al. [23] defined success as either ≥ 3
bowel motions per week or ≥ 50% improvement in
straining or ≥ 50% improvement in incomplete evacua-
tion. Other definitions of sustained treatment success
included a statistically significant reduction in Cleveland
Clinic Score and SF-36 from baseline [25], patient
reported clinical improvement [27,28] and 50%
improvement in bowel function (recorded on bowel
diaries [26]). The percentage of initial study recruits
providing data at final follow up varied between studies,
from 25 to 76% (Table 1) denoting significant attrition
in prospective studies.
Accepting variation in definitions used, random effects
meta-analysis found the overall SNS response rate (i.e. to
those beginning treatment but not necessarily implanted)
to be 56.9% (95% CI: 46.8% to 66.7%), I2 = 71%. Long
term overall treatment success was 40.1% (95% CI:
26.3% to 54.7%), I2 = 87%, considering permanently
implanted patients only, treatment success was 73.2%
(95% CI: 57.5% to 86.6%), I2 = 80% (Fig. 4).
Overall, success seemed to be dichotomised with four
studies [21,23,25,26] demonstrating higher success
rates, both in the short and long term, than others. The
largest of these, by Govaert et al. [21], is a retrospective
study at two centres in The Netherlands and Denmark,
with follow up at 1, 3, 6 and 12 months (although this is
difficult to verify for a retrospective study). It appears that
data were collected during routine clinical follow up
rather than as part of a planned research study. There was
considerable drop-out with Wexner scores available for
only 32 (47% of implanted cases) at 6 months. A multi-
centre prospective cohort study [23] demonstrated the
highest positive response rate to temporary SNS, as well
as a high long term success rate (87% of patients with per-
manent implants); the primary outcome was an improve-
ment in one of three domains; bowel frequency, straining
and incomplete evacuation, assessed using questionnairesT
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and validated symptom scores. However, treatment suc-
cess was assessed on last follow up and there was a high
drop-out rate (38% drop-out at 24 months). A further
retrospective study [26] of 21 patients in a single centre
demonstrated a 47% success rate based on patient
reported outcomes and laxative use. Ratto et al. [25]
used a retrospective study design to evaluate outcome
based on validated questionnaires. Although 32/42
(76%) of patients still had implant at the end of follow up
(and therefore considered to be responders to some
degree), only 15 (35%) had a 50% reduction of Cleveland
Clinic Score. Three studies [24,27,28] demonstrated rel-
atively poor efficacy of treatment (Table 4). Two of these
are retrospective case series while the other [27] studied
neurological constipation only.
Summary evidence statements: efficacy
1 Data on efficacy were inconsistently measured with
high drop-out rates and heterogeneous findings,
making estimates tentative and imprecise [level IV]
2 Pooled treatment success was typically 57–87% for
patients receiving permanent implants, although
there was significant variation between studies [level
IV]
Patient selection
Patient selection was inconsistent between the seven
studies. There was no unifying criteria for establishing
a diagnosis of chronic constipation (Table 5). Four
studies excluded patients with neurological disease and
one study only included patients with neurological
disease. The proportion of participants with slow tran-
sit constipation (STC) was recorded in six of the
studies. There was no significant difference in
response to SNS when studies were grouped by those
with less or more than 50% of patients with STC
(Fig. 5). Defaecating proctograms were performed in
six of the studies but only used to stratify patients in
two studies (Table 5).
Figure 2 Forest plot showing rates of total procedural compli-
cations (percentage of patients).
Figure 3 Forest plot showing rates of device explantation rate
(percentage of patients).
Table 3 Harms.
Author
Total
N
Implanted
N
Total complications
resulting in
reoperation
Total adverse
events
Infection
resulting in
device removal
Explantation
(permanent
device removal)
Additional
surgery
Kamm [23] 62 45 11/45 (24%) 101 2/45 (4%) 2/45 (4%)
(7/45 exit study)
Subtotal colectomy
1
Sharma [26] 21 11 3/11 (27%) NR 0 0 NR
Ortiz [24] 48 23 9/23 (39%) NR 1/23 (4%) 6/23 (27%) NR
Govaert [21] 117 68 9/68 (13%) NR 3/68 (4.4%) 9/68 (13%) NR
Khan [27] 22 12 0 1 0 0 NR
Ratto [25] 61 42 14/42 (33%) 9 0 8/42 (19%) NR
Graf [28] 44 15 5/15 (33%) 12 PNE
5 PERM
1/15 (7%) 4/15 (27%) Stoma 2
Colectomy 2
Appendicostomy 1
NR, not reported.
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Summary evidence statements: patient selection
1 All studies included variable phenotypes of chronic
constipation making populations heterogeneous
(Level IV).
2 No conclusions could be drawn regarding particular
phenotypes that responded favourably or unfavour-
ably to SNS (Level IV).
Discussion
The possibility of a minimally invasive technique is a
very attractive option for the management of patients
with chronic constipation, especially as alternative
options may involve potentially hazardous major surgery
with colectomy and uncertain outcome. This systematic
review has identified a number of published series that
might suggest benefit of this treatment, with a pooled
‘success rate’ of 73% of those patients undergoing per-
manent implantation and a device removal rate of
around 12%. These findings would certainly merit fur-
ther study but must be treated with caution as the
majority of the studies were retrospective case series.
There was evidence of considerable loss to follow up,
irregular and imprecise measurement of outcomes, and
ill-defined post-hoc analysis of the data. The outcomes
were, for the most part, reported to the clinicians pro-
viding the treatment and there is a well-recognised
reporting bias here. In addition there may be a strong
publication bias [29].
Several important studies were not included in the
review but merit consideration in the discussion. A ran-
domised, double-blind, placebo-controlled, two-phase
crossover study by Dinning et al. [30] comparing sham,
subsensory and suprasensory stimulation in patients
with STC was excluded from the review due to inade-
quate follow up period (< 12 months). The primary
outcome measure was the proportion of patients who,
on more than 2 days per week for at least 2 of 3 weeks,
Figure 4 Forest plot showing rates of implant long-term suc-
cess rate (percentage of patients).
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reported a bowel movement associated with a feeling of
complete evacuation. This well-conducted trial showed
no clinical effect of sub- or suprasensory stimulation
over sham in 55 patients undergoing permanent SNS
implantation. The proportion of patients who met the
primary outcome measure did not differ between
suprasensory (30%) and sham (21%) stimulations nor
between subsensory (25%) and sham (25%) stimula-
tions. In addition there was no significant change in
quality of life scores. Long term data from this study
have been reported since the systematic review was
completed noting that 88% of patients in the original
study [30] had undergone device removal at median
follow up 5.7 years [31].
A French group have presented data on 20 patients
undergoing permanent SNS after a successful 3-week
temporary test. A randomised on/off sham controlled
sub-sensory stimulation was provided (8 weeks each
cycle) with no improvement during active stimulation.
At 1 year, only 11 (55%) patients were still responding
[32]. The results of a third study have been recently pre-
sented (nationally and internationally) from a multi-cen-
tre prospective randomised study [ISRCTN44563324].
The main aim of this study was to assess the efficacy of
sham controlled tined lead stimulation as a way of iden-
tifying true responders. Thirty-nine patients were
recruited to the test phase and 27 were implanted with
all but one followed up to 6 months. The findings
showed, once again, that temporary testing has no value
in determining long term response. The response at
6 months was assessed by a reduction of at least 0.5 on
Table 5 Patient baseline phenotypic data.
Authors N Inclusion criteria STC Neurological disease Proctogram
Kamm [23] 62 < 2 bowel movements per week and/or
straining or incomplete emptying > 25%
occasions
50 (81%) Excluded Performed not stratified
Sharma [26] 21 2 or fewer bowel movements per week, failed
conservative treatment over at least
12 months from GP referral
19 (86%) Excluded Performed used to rule out obstructive
defaecation but anismus not exclusion
criterion
Ortiz [24] 48 Rome III criteria, symptoms at least 1 year,
failed conservative treatment with laxatives,
suppositories, enemas and behavioural therapy
5 (10%) Excluded Performed not stratified
Govaert [21] 117 < 2 bowel movements per week and/or
straining or incomplete emptying > 25%
occasions. Persistent symptoms 1 year and
failed conservative treatment (NB includes 26
patients from Kamm study and 38 patients
from Maeda study)
75 (64%) Not excluded Performed not stratified
Khan [27] 22 Patients with neurological disease [including
multiple sclerosis (n = 14) and spinal cord
injury (n = 5)] and severe constipation
refractory to conservative treatment
NR Inclusion criterion None
Ratto [25] 61 Rome III criteria. Patients identified from
GINS: Italian group for sacral nerve
neuromodulation (NB may include some
patients from Ortiz study although not
specifically mentioned)
17 (28%) Not excluded Performed and patients with rectocoele,
intussusception, rectal prolapse and
enterocoele excluded
Graf [28] 44 History of ‘constipation’ for at least 6 months
and failure of conservative treatment
21 (48%) Excluded spinal
cord injury
Selective
Figure 5 Forest plot showing rates of SNS response rate by
level of STC patients (percentage of patients). KEY: STC, slow
transit constipation.
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PAC-SYM and this was achieved in 15(55%) of
patients.
These more recent prospective studies suggest that
the efficacy of SNS in constipation may be very limited,
but in particular, that prediction of responders using
various temporary testing regimens is poor. In view of
the cost and risk of the procedure, the inability to pre-
dict responders is likely to hamper the utility of the
treatment in the future.
There was a significant difference in the conclusions
between the largely retrospective early studies, which
supported the use of SNS, and the three recent well-
conducted prospective studies, which have all urged
greater caution. This is an example of the importance
and need for formally planned and robustly executed
studies to inform surgical practice and a warning against
over-reliance on retrospective cohort studies.
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